Faruqi and Faruqui, LLP Logo
Share this page

Agile Therapeutics, Inc. (AGRX)

NASDAQ:AGRX

Summary

Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $50,000 Investing In Agile Therapeutics, Inc. To Contact The Firm

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential securities fraud at Agile Therapeutics, Inc. (“Agile” or the “Company”) (NASDAQ:AGRX).

The investigation focuses on whether the Company and its executives violated federal securities laws.

Specifically, aftermarket hours on January 3, 2017, the Company released data from its Phase 3 SECURE study evaluating the Company’s contraceptive patch, Twirla.  Among the results, the Company stated that 51.4% of subjects had withdrawn from the study and that 1.7% of test subjects suffered “serious adverse events.”  On this news, Agile’s share price significantly declined.

Take Action

If you invested in Agile stock or options and would like to discuss your legal rights, please fill out the form below.  You can also contact us by calling Richard Gonnello toll free at 877-247-4292 or at 212-983-9330 or by sending an e-mail to rgonnello@faruqilaw.com.  Faruqi & Faruqi, LLP also encourages anyone with information regarding Agile’s conduct to contact the firm, including whistleblowers, former employees, shareholders and others.

Request Information

Please tell us about yourself by completing the form and we will provide you with additional
information on how to join the Class Action at no cost to you.

  • Case:
    Agile Therapeutics, Inc. (AGRX)
  •    

* The submission of this form does not create an attorney-client relationship.

Contact Counsel

Richard W. Gonnello
Faruqi & Faruqi, LLP
685 Third Avenue 26th Floor
New York, NY 10017
Tel: (212) 983-9330

Email:

Case Details

Date:

  • 01/09/2017

Send Information

If you have information regarding this case that you would like to make available, please click here to contact us about our investigation.